Our Blog:

30 years of cell culture excellence

Author: Biological Industries

Advanced Therapies Research Grant

The Sartorius/BI Advanced Therapies Grant Program aims to support academic researchers developing hPSC, hMSC, or human immune cell research and applications that will help advance medical progress in the fields of regenerative medicine and cell-based therapies by offering full-scale serum- and xeno-free cell culture solutions. Winners will receive: Up to $25,000 in state-of-the-art media and reagentsSix (6) months of dedicated scientific support and technical consultation To apply for a chance to win up to $25,000 in AT media and reagents and dedicated scientific support for up to six (6) months, please submit your proposal online and send any additional...

Read More

What are hMSCs and why they are ideal for therapeutic applications

What are Mesenchymal Stem Cells (MSCs)? Before we delve into the advantages of using mesenchymal stem cells (MSCs) for therapeutic applications, let’s begin with a quick explanation of what they are. These cells, which are also known as mesenchymal stromal cells, were first discovered by Friedenstein and his colleagues in 1976 from bone marrow, and have since become an increasing focus of stem cell research and therapies. According to the International Society for Cellular Therapy (ISCT), MSCs are defined as cells that follow these minimal criteria: They must be plastic-adherent when maintained in standard culture conditions They must express...

Read More

Biological Industries USA announces Growth and Recruitment of New Hires

Connecticut-based cell culture products provider announces new positions as it looks to expand in response of the success of its stem cell reagents and custom media manufacturing business Cromwell, CT – December 15, 2017 – Biological Industries USA (BI-USA), a premium cell culture products and services provider to the academic, biotech, and pharmaceutical industries, announced its plans today to hire for several new positions throughout the United States. The company has begun recruitment for energetic candidates passionate about stem cell research and who thrive in highly competitive markets to support its projected growth over the next several years. Biological Industries...

Read More

Spotlight on iPSC production

Biological Industries sponsors RegMedNet 2-month focus on the production of iPSCs March 31, 2017 (RegMedNet.com) Induced pluripotent stem cells (iPSCs) are arguably one of the hottest topics within regenerative medicine. The first generation of iPSCs 10 years ago marked a huge milestone in the field, leading to great progress from disease modeling to development of new, personalized therapeutic approaches for numerous conditions. Key advantages include the potential low-cost manufacture of personalized medicines, omitting the need to use embryonic or fetal stem cells, efficiency of genetic manipulation compared with somatic cells and providing a source for cells that may otherwise...

Read More

Follow Us

Subscribe